Pulmonary toxicity after intraperitoneal mitomycin C: a case report of a rare complication of HIPEC

World Journal of Surgical Oncology

Case Report

George Kokosis¹  Dan G. Blazer¹  Melissa L. Abel² 

[1] Department of Surgery, Duke University Medical Center, Box 3247, 27710, Durham, NC, USA;School of Medicine, Duke University Medical Center, Box 3247, 27710, Durham, NC, USA;

关键词: Appendiceal cancer;    Intraperitoneal chemotherapy;    Mitomycin C;    Pulmonary toxicity;    ARDS;   

DOI  :  10.1186/s12957-016-1047-6

 received in 2016-07-07, accepted in 2016-11-07,  发布年份 2017

来源: Springer

【 摘 要 】

BackgroundCytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) has become a common treatment approach for disseminated appendiceal neoplasms. Systemic absorption of intraperitoneal chemotherapeutics may lead to drug-induced toxicity, most commonly neutropenia. Mitomycin C has been the most commonly used chemotherapeutic in HIPEC for the past several decades.Case presentationHere, we describe a rare pulmonary complication secondary to intraperitoneal administration of mitomycin C.ConclusionsWhile rare, intraperitoneal mitomycin C has the potential to cause serious pulmonary toxicity that should be considered with administration. To our knowledge, this report represents only the second case described in the literature.

【 授权许可】

CC BY   
© The Author(s). 2016